CGH analysis of ductal carcinoma of the breast with basaloid/myoepithelial cell differentiation

Jones, C; Nonni, A V; Fulford, L; Merrett, S; Chaggar, R; Eusebi, V; Lakhani, S R
August 2001
British Journal of Cancer;8/1/2001, Vol. 85 Issue 3, p422
Academic Journal
2-18% of ductal carcinoma-No Special Type (NST) are reported to express basal cell keratin 14 and such tumours may have a different metastatic pattern and prognosis. We performed immunohistochemistry for cytokeratins 19 (luminal) and 14 (basal) on 92 ductal carcinoma-NST. Those tumours showing CK14 expression were further characterized by immunohistochemistry for myoepithelial cell phenotype and analysed by comparative genomic hybridization. The 7 cases of ductal carcinoma-NST exhibiting a basal cell phenotype were all grade III tumours and showed a molecular cytogenetic profile similar to more conventional myoepithelial cell carcinomas. Therefore it appears that grade III invasive ductal carcinomas contain a subset of tumours with specific morphological and cytogenetic characteristics, and probably prognosis for the patient.


Related Articles

  • Loss of SOCS3 expression is associated with an increased risk of recurrent disease in breast carcinoma. Mingzhen Ying; Dawei Li; Linjun Yang; Mei Wang; Ning Wang; Ying Chen; Miaoxia He; Yajie Wang // Journal of Cancer Research & Clinical Oncology;Oct2010, Vol. 136 Issue 10, p1617 

    Constitutive activation of JAK/STAT pathway is observed in various solid tumors and hematological malignancies. SOCS3 acts as a key negative regulator of JAK/STAT pathway and represents one of the candidate tumor suppressor genes. In the current study, we aimed to evaluate SOCS3 expression in...

  • Genomic and phenotypic analysis of BRCA2 mutated breast cancers reveals co-occurring changes linked to progression.  // Breast Cancer Research;2011, Vol. 13 Issue 4, p3020 

    The article focuses on the genomic and phenotypic analysis of BRCA2 related to breast cancers that helps in revealing several changes linked to the progression of cancer. It mentions that tumors from BRCA2 carriers related to luminal and basal/triple-negative phenotypes (TNPs) differs in the...

  • Study of phospho-β-catenin subcellular distribution in invasive breast carcinomas in relation to their phenotype and the clinical outcome. Nakopoulou, Lydia; Mylona, Eleni; Papadaki, Ioanna; Kavantzas, N.; Giannopoulou, I.; Markaki, S.; Keramopoulos, A. // Modern Pathology;Apr2006, Vol. 19 Issue 4, p556 

    β-Catenin has a crucial role in cell–cell adhesion as well as a signaling role as a member of the Wnt pathway. The aim of this study was to examine the clinicopathological and prognostic value of phosphorylated β-catenin, as well as its relation to the tumors’ phenotype, in...

  • Glycolytic phenotype in breast cancer: activation of Akt, up-regulation of GLUT1, TKTL1 and down-regulation of M2PK. Schmidt, Melanie; Voelker, Hans-Ullrich; Kapp, Michaela; Krockenberger, Mathias; Dietl, Johannes; Kammerer, Ulrike // Journal of Cancer Research & Clinical Oncology;Feb2010, Vol. 136 Issue 2, p219 

    Metabolic dependence on glucose utilisation has been described for different tumours characterised by activation of Akt, upregulation of GLUT1, M2PK and TKTL1. To date, however, little is known about glucose metabolism in breast cancer tissue. We analysed 55 breast cancer specimens, 26 adjacent...

  • Peritumoral vascular invasion and NHERF1 expression define an immunophenotype of grade 2 invasive breast cancer associated with poor prognosis.  // BMC Cancer;2012, Vol. 12 Issue 1, p106 

    The article offers information on a study conducted by the authors related to peritumoral vascular invasion and NHERF1 tumor marker expression in invasive breast cancer, that is associated with poor prognosis. It states that prognostic factors and tumor markers were investigated in 187 invasive...

  • Identification of key clinical phenotypes of breast cancer using a reduced panel of protein biomarkers. Green, A R; Powe, D G; Rakha, E A; Soria, D; Lemetre, C; Nolan, C C; Barros, F F T; Macmillan, R D; Garibaldi, J M; Ball, G R; Ellis, I O // British Journal of Cancer;10/1/2013, Vol. 109 Issue 7, p1886 

    Background:Breast cancer is a heterogeneous disease characterised by complex molecular alterations underlying the varied behaviour and response to therapy. However, translation of cancer genetic profiling for use in routine clinical practice remains elusive or prohibitively expensive. As an...

  • Prognostic Relevance of Basal Cytokeratin Expression in Operable Breast Cancer. Potemski, Piotr; Kusinska, Renata; Watala, Cezary; Bednarek, Andrzej K.; Kordek, Radzislaw; Pluciennik, Elzbieta // Oncology;2005, Vol. 69 Issue 6, p478 

    Objective: We investigated whether basal cytokeratin (CK5/6 or CK17) expression had an impact on survival in patients with operable breast cancer. Methods: Expression of CK5/6 or CK17 was analyzed by immunohistochemistry in 195 women with breast cancer. Results: In total, 72 (37%) tumor samples...

  • Serglycin Is Implicated in the Promotion of Aggressive Phenotype of Breast Cancer Cells. Korpetinou, Angeliki; Skandalis, Spyros S.; Moustakas, Aristidis; Happonen, Kaisa E.; Tveit, Heidi; Prydz, Kristian; Labropoulou, Vassiliki T.; Giannopoulou, Efstathia; Kalofonos, Haralambos P.; Blom, Anna M.; Karamanos, Nikos K.; Theocharis, Achilleas D. // PLoS ONE;Oct2013, Vol. 8 Issue 10, p1 

    Serglycin is a proteoglycan expressed by some malignant cells. It promotes metastasis and protects some tumor cells from complement system attack. In the present study, we show for the first time the in situ expression of serglycin by breast cancer cells by immunohistochemistry in...

  • Molecular profiling of breast cancer in Nigerian women identifies an altered p53 pathway as a major mechanism underlying its poor prognosis compared with British counterpart. AGBOOLA, Ayodeji O. J.; BANJO, Adekunbiola A. F.; ANUNOBI, Charles C.; AYOADE, Babatunde A.; DEJI-AGBOOLA, Anotu Mopelola; MUSA, Adewale A.; ABDEL-FATAH, T.; NOLAN, Christopher C.; RAKHA, Emad A.; ELLIS, Ian O.; GREEN, Andrew R. // Malaysian Journal of Pathology;Apr2014, Vol. 36 Issue 1, p3 

    Background: Advances in breast cancer (BC) research have demonstrated differences between black and white women with regarding tumour behaviour, patient outcome and response to treatment which can be explained by underlying genetic changes. The tumour suppressor gene p53 has been speculated to...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics